
CONMED Corporation CNMD
$ 45.89
-0.18%
Annual report 2025
added 02-17-2026
CONMED Corporation Accounts Receivables 2011-2026 | CNMD
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables CONMED Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 248 M | 238 M | 242 M | 191 M | 184 M | 177 M | 189 M | 182 M | 167 M | 148 M | 134 M | 129 M | 140 M | 139 M | 136 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 248 M | 129 M | 176 M |
Quarterly Accounts Receivables CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 225 M | 234 M | 221 M | 231 M | 239 M | 241 M | 230 M | 229 M | 213 M | 191 M | 197 M | - | 183 M | 184 M | 165 M | 169 M | 164 M | 177 M | 177 M | 177 M | 177 M | 189 M | 189 M | 189 M | 189 M | 182 M | 182 M | 182 M | 182 M | 167 M | 167 M | 167 M | 167 M | 148 M | 148 M | 148 M | 148 M | 134 M | 134 M | 134 M | 134 M | 129 M | 129 M | 129 M | 129 M | 140 M | 140 M | 140 M | 140 M | 139 M | 139 M | 139 M | 139 M | 136 M | 136 M | 136 M | 136 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 241 M | 129 M | 169 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Delcath Systems
DCTH
|
11.7 M | $ 9.11 | -10.77 % | $ 260 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
97.3 M | $ 13.94 | -0.71 % | $ 2.09 B | ||
|
Cognyte Software Ltd.
CGNT
|
175 M | $ 7.0 | 5.74 % | $ 503 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.38 | -4.58 % | $ 163 M | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Apyx Medical Corporation
APYX
|
14 M | $ 3.49 | 2.05 % | $ 121 M | ||
|
AxoGen
AXGN
|
26.2 M | $ 31.87 | 2.07 % | $ 1.47 B | ||
|
Aziyo Biologics
AZYO
|
3.26 M | - | 1.37 % | $ 20.5 M | ||
|
Bio-Rad Laboratories
BIO
|
452 M | $ 275.33 | 2.19 % | $ 7.77 B | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
566 M | $ 40.88 | 2.48 % | $ 6.09 K | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
InMode Ltd.
INMD
|
10.5 M | $ 14.0 | 0.29 % | $ 905 M | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
4.71 M | $ 14.09 | -7.06 % | $ 381 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
112 K | $ 2.48 | 1.02 % | $ 146 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
24.7 M | $ 24.18 | 1.09 % | $ 204 M | ||
|
Establishment Labs Holdings
ESTA
|
65 M | $ 77.41 | -1.12 % | $ 2.18 B | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
679 M | $ 96.27 | 0.06 % | $ 13 B | ||
|
Tandem Diabetes Care
TNDM
|
165 M | $ 26.14 | 0.5 % | $ 1.78 B | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 2.11 | -2.76 % | $ 1.28 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 11.13 | -4.01 % | $ 857 M | ||
|
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.73 | 2.57 % | $ 39.7 M | ||
|
Inogen
INGN
|
29.6 M | $ 6.4 | 6.53 % | $ 151 M | ||
|
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
10.6 M | $ 102.4 | 1.89 % | $ 1.3 B |